Loading company…
New York-based biopharma developing radioimmunotherapy and antibody treatments for pediatric oncology, led by DANYELZA.
Y-mAbs Therapeutics, Inc., founded in 2014 and headquartered in New York, US, develops and commercializes radioimmunotherapy and antibody-based treatments for pediatric oncology and other hard-to-treat diseases. Its flagship product, DANYELZA (naxitamab-gqgk), targets high-risk neuroblastoma and is sold mainly to hospitals and specialty clinics in North America and Europe. The company completed an IPO in September 2018, raising USD 96 mn by selling 6 million shares at USD 16 each. In 2024 it reported revenue of USD 87.69 mn and EBITDA of USD -30.67 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in